drugset / Trial / NCT05364931

A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

NCT05364931

Phase 2 Completed 54 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of cotadutide in participants with non-cirrhotic NASH with fibrosis.

Timeline

Start
2022-07-14
Primary completion
2024-04-19
Completion
2024-04-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Cotadutide Peptide 300 ug Subcutaneous
Subject Cotadutide Peptide 600 ug Subcutaneous